FDC Limited has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors also approved the re-appointment of M/s. GMVP & Associates LLP as Cost Auditor and M/s. Ford, Rhodes, Parks & Co. as Tax Auditor for the financial year 2026-2027.

FDC Limited is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of pharmaceutical products. The company’s operations include a range of therapeutic products and healthcare solutions. For the quarter ended March 31, 2026, the company reported a standalone revenue from operations of ₹56,436.37 lakhs, compared to ₹45,794.05 lakhs in the previous quarter and ₹48,200.43 lakhs in the corresponding quarter of the previous year. The standalone net profit after tax stood at ₹10,707.03 lakhs for the quarter ended March 31, 2026, showing growth against ₹2,718.71 lakhs in the previous quarter and ₹4,821.55 lakhs in the corresponding quarter of the previous year.